The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.

Smith L, Mosley J, Yates J, Caswell L. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. J Pharm Pharm Sci. 2016; 19(1):137-46.

View in: PubMed

subject areas

Enzyme Inhibitors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias

authors with profiles

Lillian Smith

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support